Brokers Issue Forecasts for EYPT FY2025 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim anticipates that the company will post earnings of ($2.49) per share for the year. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.06). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $10.52 million during the quarter, compared to the consensus estimate of $12.35 million.

EYPT has been the subject of several other research reports. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price objective for the company. Robert W. Baird dropped their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating for the company in a research report on Monday, November 11th. Chardan Capital upped their target price on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $18.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $26.63.

EyePoint Pharmaceuticals Stock Up 11.1 %

EYPT stock traded up $0.85 during trading on Wednesday, hitting $8.48. The company had a trading volume of 606,496 shares, compared to its average volume of 814,893. The firm has a 50-day moving average price of $8.24 and a 200-day moving average price of $8.95. EyePoint Pharmaceuticals has a 12 month low of $6.90 and a 12 month high of $30.99. The stock has a market cap of $578.76 million, a price-to-earnings ratio of -4.25 and a beta of 1.49.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Essex Investment Management Co. LLC boosted its stake in shares of EyePoint Pharmaceuticals by 234.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 142,144 shares of the company's stock worth $1,136,000 after buying an additional 99,606 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of EyePoint Pharmaceuticals by 5.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company's stock worth $1,141,000 after buying an additional 7,967 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of EyePoint Pharmaceuticals by 16.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company's stock worth $9,583,000 after buying an additional 166,699 shares during the last quarter. Barclays PLC boosted its stake in shares of EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock worth $1,959,000 after buying an additional 197,033 shares during the last quarter. Finally, Patient Square Capital LP acquired a new position in shares of EyePoint Pharmaceuticals during the 3rd quarter worth about $10,882,000. 99.41% of the stock is owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.